Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 15/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.69 |
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.53 |
| ▸ | MGAM | O43451 | 2/20 | 0.53 |
| ▸ | SI | P14410 | 2/20 | 0.53 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29515065 | 1.00 | GAA (0.69) | GAAKDM4EALDH1A1MAPTHSD17B10 | |
| Bromide SCHEMBL25420644 | 0.98 | GAA (0.67) | GAAKDM4EALDH1A1MAPTHSD17B10 | |
| Hydrochloric Acid SCHEMBL29609753 | 0.98 | GAA (0.67) | GAAKDM4EALDH1A1MAPTHSD17B10 | |
| Acetic Acid SCHEMBL4004465 | 0.92 | GAA (0.59) | GAAKDM4EALDH1A1MAPTHSD17B10 | |
| Trifluoroacetic Acid SCHEMBL29988639 | 0.86 | GAA (0.53) | GAAKDM4EALDH1A1MAPTHSD17B10 | |
| SCHEMBL94134 | 0.85 | GAA (0.69) | GAAKDM4EALDH1A1MAPTHSD17B10 | |
| SCHEMBL2450078 | 0.84 | KDM4E (0.71) | GAAKDM4EALDH1A1MAPTHSD17B10 | |
| SCHEMBL1230426 | 0.82 | GAA (1.00) | GAAKDM4EALDH1A1MAPTHSD17B10 | |
| SCHEMBL5898250 | 0.78 | HSD17B3 (0.50) | GAAKDM4EALDH1A1MAPTHSD17B10 | |
| Acetic Acid SCHEMBL472754 | 0.78 | POLB (0.60) | GAAKDM4EALDH1A1MAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108885975-A | Pattern forming method, production method, the production method of optical component, the production method of circuit board, the production method of the production method of electronic component and imprint mold for processing substrate | 佳能株式会社 | 2018-11-23 | — | — | CN | claimed |
| CN-108148033-A | A kind of fluorescence probe Cou-Bu and its preparation and the application in ozone detection | 中国科学院大连化学物理研究所 | 2018-06-12 | — | — | CN | claimed |
| CN-105368373-A | Preparation method of ultraviolet curing adhesive | MEI QINGBO | 2016-03-02 | — | — | CN | claimed |
| EP-2150623-B8 | METHOD FOR MEASURING THE PLASMINE ACTIVITY OF MICROPARTICLES PRESENT IN A SAMPLE OF A BIOLOGICAL FLUID AND USE THEREOF | INST NAT SANTE RECH MED (FR) | 2012-12-19 | — | — | EP | claimed |
| US-20110171196-A1 | METHODS OF TREATMENT AND USES FOR CAMKII AND ITS INTERACTION WITH HDACS AND CALPAIN | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-07-14 | — | — | US | claimed |
| EP-2150623-A2 | METHOD FOR MEASURING THE PLASMINE ACTIVITY OF MICROPARTICLES PRESENT IN A SAMPLE OF A BIOLOGICAL FLUID AND USE THEREOF | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2010-02-10 | — | — | EP | claimed |
| WO-2009004189-A2 | METHOD FOR MEASURING THE PLASMINE ACTIVITY OF MICROPARTICLES PRESENT IN A SAMPLE OF A BIOLOGICAL FLUID AND USE THEREOF | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2009-01-08 | — | — | WO | claimed |
| EP-1962888-A2 | USES FOR CAMKII AND HDACS IN THE TREATMENT OF HEART CONDITIONS | MYOGEN, INC. (US) | 2008-09-03 | — | — | EP | claimed |
| WO-2007059533-A2 | USES FOR CAMKI I AND HDACS IN THE TREATMENT OF HEART CONDITIONS | MYOGEN, INC. (US) | 2007-05-24 | — | — | WO | claimed |
| CN-1865995-A | Method for evaluating effect of seriously-polluted lake dredging on bottom mud microbe ecological system structure and function | NANJING INST GEO & LIMNOLOGY (CN) | 2006-11-22 | — | — | CN | claimed |
| US-6288037-B1 | C-TERMINALLY MODIFIED PENTAPEPTIDES CONTAINING VALINE AND ASPARTIC ACID | BASF AKTIENGESELLSCHAFT (DE) | 2001-09-11 | — | — | US | claimed |
| EP-0880542-A2 | SUBSTRATES AND INHIBITORS FOR CYSTEINE PROTEASE ICH-1 | BASF AG (US) | 1998-12-02 | — | — | EP | claimed |
| WO-1997027220-A2 | SUBSTRATES AND INHIBITORS FOR CYSTEINE PROTEASE ICH-1 | BASF AG (US) | 1997-07-31 | — | — | WO | claimed |
| EP-0516814-A4 | METHOD AND COMPOSITION FOR DETERMINING ANTIMICROBIAL SUSCEPTIBILITY OF THE MAJORITY OF CLINICALLY SIGNIFICANT GRAM POSITIVE ORGANISMS | BAXTER DIAGNOSTICS INC (US) | 1994-06-01 | — | — | EP | claimed |
| EP-0516814-A1 | METHOD AND COMPOSITION FOR DETERMINING ANTIMICROBIAL SUSCEPTIBILITY OF THE MAJORITY OF CLINICALLY SIGNIFICANT GRAM POSITIVE ORGANISMS. | BAXTER DIAGNOSTICS INC (US) | 1992-12-09 | — | — | EP | claimed |
| WO-1992012257-A1 | METHOD AND COMPOSITION FOR DETERMINING ANTIMICROBIAL SUSCEPTIBILITY OF THE MAJORITY OF CLINICALLY SIGNIFICANT GRAM POSITIVE ORGANISMS | BAXTER DIAGNOSTICS INC. (US) | 1992-07-23 | — | — | WO | claimed |
| US-12503453-B2 | USP7 inhibition | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| EP-4590297-A2 | THERAPEUTIC COMBINATIONS COMPRISING UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS AND PARP1-SELECTIVE INHIBITORS | KSQ Therapeutics, Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| WO-1992012257-A1 | METHOD AND COMPOSITION FOR DETERMINING ANTIMICROBIAL SUSCEPTIBILITY OF THE MAJORITY OF CLINICALLY SIGNIFICANT GRAM POSITIVE ORGANISMS | BAXTER DIAGNOSTICS INC. (US) | 1992-07-23 | — | — | WO | disclosed |
| EP-0347771-A2 | Device for enhancing fluorescence and kinetics and methods of using the device | Becton, Dickinson and Company (US) | 1989-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503453-B2 | USP7 inhibition | USP7, USP47, USP2 | GAA 180/4885KDM4E 1761/4885ALDH1A1 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.